NCT06689241Recruiting
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- First submitted
- 13 Nov 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Alexandria University
- Diseases
- Obesity
- NCT number
- NCT06689241
What you commit to
- Study type: Interventional
- Planned participants: 162
- From 1 Oct 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe cardiac disorder
- chronic renal failure
- major psychological disorder
Other
- liver cirrhosis
Who the study is looking for
- Age: 20-60 years, both sexes.
- ASA physical status class I to III.
- BMI 35-50 kg/m²
Age in the registry: 20 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria university Coordinator of this site? Confirm its status | Alexandria | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.